top of page

Search


Compass Pathways Hits Milestone in Psychedelic Drug Development with Phase 3 Psilocybin Readout for 250+ Patients
Compass Pathways has become the first company to publish Phase 3 data for a classical psychedelic. Its synthetic psilocybin candidate,...
Jun 23, 2025


Psilocybin for Depression: A Closer Look at the Evidence
With the rise of companies exploring psilocybin based drugs to treat various mental health conditions, the need for greater evidence...
May 19, 2025


Microdosing Psilocybin for Women’s Health: Endometriosis, PMDD & Menopause | Mabel
Mabel: Microdosing Psilocybin for Women’s Health
Apr 6, 2025


Could Psychedelic Therapies Offer New Hope for Alzheimer's Disease?
Alzheimer’s Disease (AD) is a pressing global challenge, with cases expected to triple globally, affecting around 152 million people by...
Mar 29, 2025


Research: Psilocybin Microdosing Boosts Emotional Stability and Reduces Depression and Anxiety Symptoms.
The global burden of mental health disorders is rising, with depression and anxiety leading the charge as major contributors to...
Feb 7, 2025
bottom of page
